Researchers detail the complex interaction between alpha synuclein and the prion protein PrPc.
A new study reports on how the clinical profiles of Lewy body dementia differ from Alzhiemer's or Parkinson's disease.
A new study adds to the growing body of evidence that Parkinson's disease may start in the gut. Researchers found gut-to-brain propagation of alpha-synuclein spread via the vagus nerve. The study provides a more accurate model of Parkinson's progression and could lead to new treatments to halt or prevent this neurodegenerative disease.
Researchers report proteins produced by gut bacteria may cause protein misfolding in the brain and cerebral inflammation.
Using a two-photon microscope capable of peering deep within living tissue, researchers at the University of California, San Diego School of Medicine have found new evidence that alpha-synuclein protein build-up inside neurons causes them to not only become leaky, but also to misfire due to calcium fluxes.
A new Nature Communications study reveals increased calcium levels in brain cells may play a significant role in the development of Parkinson's disease.
A new PNAS study reveals an FDA approved drug that targets toxic protein interactions could be used as a novel treatment for Parkinson's disease.
A new study sheds light on how ziram causes the loss of the main source of dopamine in the central nervous system.
Mutations in the alpha-synuclein gene can cause increased vulnerability to pesticides, which may lead to Parkinson's disease.
Researchers report analyzing a person's tears may help doctors diagnose Parkinson's disease. The study reveals those with Parkinson's had increased levels of oligomeric alpha synuclein in their tears compared to those without the neurodegenerative disease.
A new study reveals information about life expectancy for those with Parkinson's and other synucleinopathies.
T cells that react to alpha-synuclein are most abundant in the early stages of Parkinson's disease but tend to disappear as the disease progresses. Signs of autoimmunity can appear in Parkinson's patients up to ten years before a diagnosis of the neurodegenerative disease. The detection of T cell response could be an early biomarker for Parkinson's, long before the physical symptoms begin to manifest.
